Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Hygroscopic. Store away from water/moisture and oxidizing agents. Keep the container tightly closed and place it in a cool, dry and well ventilated condition. Store under inert gasManufacturer Supply Intermediates of Aripiprazole With High Purity Aripiprazole API CAS 129722-12-9 1-(2,3-Dichlorophenyl)piperazine Hydrochloride CAS 119532-26-2 7-Hydroxy-3,4-Dihydro-2(1H)-Quinolinone CAS 22246-18-0 7-(4-Bromobutoxy)-3,4-Dihydro-2(1H)-Quinolinone CAS 129722-34-5| Item | Specifications |
| Appearance | White or Off-White Powder |
| Purity / Analysis Method | >99.0% (HPLC) |
| Loss on Drying | <0.50% |
| Residue on Ignition | <0.10% |
| Single Impurity | <0.50% |
| Total Impurities | <1.00% |
| Heavy Metals (as Pb) | ≤20ppm |
| Infrared Spectrum | Conforms to Structure |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Aripiprazole (CAS: 129722-12-9) |
Description:
Specifications:
Package & Storage:
| Chemical Name | 1-(2,3-Dichlorophenyl)piperazine Hydrochloride |
| Synonyms | 2,3-DCPP HCl; 1-(2,3-Dichlorophenyl)piperazine HCl; Aripiprazole EP Impurity B; Aripiprazole Related Compound C |
| CAS Number | 119532-26-2 |
| CAT Number | RF-PI2268 |
| Stock Status | In Stock, Production Capacity 30 MT/Month |
| Molecular Formula | C10H12Cl2N2·HCl |
| Molecular Weight | 267.58 |
| Melting Point | 245.0~247.0℃ |
| Storage & Sensitivity | Hygroscopic. Ambient temperatures |
| Solubility in Water | Soluble in Water |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
1-(2,3-Dichlorophenyl)piperazine Hydrochloride (CAS: 119532-26-2) is an important intermediate of Aripiprazole (CAS: 129722-12-9). Aripiprazole is a new kind of highly lipid soluble quinoline derivatives, its pharmacological effects characteristic is that it is not only the postsynaptic dopamine D 2 receptor antagonist, but also the presynaptic dopamine D 2 receptor agonist,it can also excite D 1, D 3, D 4 receptors ; it has dual effect of partial activation or receptor antagonistic on 5-HT 1A receptor; it has a completely antagonistic action on the 5-HT 2A receptor. This feature is different from the first generation, and atypical antipsychotics which belong to the second-generation antipsychotic drugs, and therefore it is called dopamine system stabilizer or third generation antipsychotic. Since it is sold in the market, it is mainly used in clinical schizophrenia, treatment of affective disorders and other psychiatric disorders. According to the literature, aripiprazole has significant effects on schizophrenia positive and negative symptoms and anxiety, depression, cognitive function, while higher safety. It was also reported that the drug can also treat other mental disorders, such as mood disorders manic episodes, senile dementia associated with mental disorders, anxiety disorders, children's behavioral disorders, depression. Nowadays,Bristol-Myers Squibb and Otsuka Pharmaceutical Company announced that the European Union has approved Abilify (aripiprazole) in the treatment of schizophrenia listing application.
